WHO to decide on Bharat Biotech's Covaxin emergency usage in October
India | September 30, 2021 14:39 ISTBharat Biotech had submitted EOI (Expression of Interest) on April 19 for its vaccine.
Bharat Biotech had submitted EOI (Expression of Interest) on April 19 for its vaccine.
Covaxin production would touch 55 million doses in October as against 35 million in September.
Bharat Biotech's Covaxin will get approval from the World Health Organisation (WHO) this week, sources told news agency ANI.
The govt had earlier this month given approval to Bharat Biotech's Ankleshwar-based manufacturing plant to produce anti-COVID vaccine Covaxin.
The ICMR in its recent study has found that the people already infected with Covid-19 while taking a dose of Covaxin have the same or increased antibody response as unaffected people taking two doses of Covaxin.
In his Independence Day speech from the ramparts of the Red Fort, PM Modi said India takes pride in having the world's largest vaccination programme, and over 54 crore people have already taken the COVID vaccines.
The first nasal vaccine against coronavirus developed by Bharat Biotech supported by Department of Biotechnology (DBT) and its PSU, Biotechnology Industry Research Assistance Council (BIRAC) has been given regulator's nod for conducting phase 2 and 3 trials, the Ministry of Science & Technology informed on Friday.
The Centre has approved a vaccine manufacturing facility for the production of Covaxin in Gujarat's Ankleshwar.
The vaccine maker stated that as of date, all batches of Covaxin were manufactured and released from its manufacturing facilities at Genome Valley, Hyderabad, which are fully audited and approved by regulatory authorities.
The approval received is from the National Institute of Pharmacy and Nutrition, Hungary certifying the GMP for the manufacture of Covaxin, a note posted on twitter said.
WHO Prequalification enables the procurement of Rotavac 5D by agencies such as UNICEF and PAHO (Pan American Health Organisation) and will fast-track global access to this life saving vaccine.
ICMR reveals that Covaxin is effective against the Delta Plus variant of COVID 19.
Responding to a question on whether it has come to the notice of the government that Covaxin used in India is not recognised by many countries, Pawar said the government is aware that Covaxin at present is not part of WHO Emergency Use Listing (EUL).
West Bengal has vaccinated over 2.75 crore people so far and out of them, 81.9 lakh got the second dose, the health official said.
The Government of India has been holding discussions with COVID-19 vaccine manufacturers Moderna and Pfizer, for procuring their vaccine. However, there has been a delay over the same.
The candidates found the Quantitative and Logical reasoning section a bit difficult, while sections like English, GK and Current Affairs were appeared to be easy.
The termination of the MoU came after the deal with the Brazilian government for supply of 20 million doses of the vaccine landed in controversy and attracted investigation by authorities in that country.
Trials for coronavirus vaccine for children are underway in the country ahead of an anticipated third wave of the pandemic.
The rolling submission process was recommended and accepted under the Minister of Health's Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19.
A decline in average daily vaccination against the coronavirus has been seen since June 21, when the new phase of universalisation of COVID-19 vaccination commenced, government data showed.
Top News
Latest News
